![]() |
市場調查報告書
商品編碼
1380394
全球胰島素貼片幫浦市場 2023-2030Global Insulin Patch Pumps Market 2023-2030 |
預計全球胰島素貼片幫浦市場在預測期內將以 9.8% 的CAGR成長。市場的成長歸因於糖尿病盛行率上升和醫療保健支出增加等因素。根據國際糖尿病聯盟的數據,到 2021 年,全球將有 5.37 億成年人(20-79 歲)患有糖尿病,比例佔全球十分之一。預計到 2030 年,這一數字將增至 6.43 億,到 2045 年將增至 7.83 億。 數百萬成年人患有葡萄糖耐受性受損 (IGT),這使他們面臨 2 型糖尿病的高風險。超過四分之三的糖尿病成人生活在低收入和中等收入國家。糖尿病造成至少 9,660 億美元的醫療支出,在過去 15 年中增加了 316%。
此外,美國食品藥物管理局 (FDA) 批准的頻率不斷增加,以及人們對先進貼片幫浦的認知不斷提高,正在加速市場成長。 2023 年 5 月,美國食品藥物管理局批准了 Beta Bionics iLet ACE 幫浦和 iLet 劑量決策軟體,適用於 6 歲以上第 1 型糖尿病患者。這兩種設備與 FDA 批准的兼容整合連續血糖監測儀 (iCGM) 一起開發了一種名為 iLet Bionic Pancreas 的新系統。這種新型自動胰島素給藥 (AID) 系統使用演算法來確定和命令胰島素輸送。
Title: Global Insulin Patch Pumps Market Size, Share & Trends Analysis Report by type (Disposable and Reusable), and by Distribution Channel (Hospitals, Private Clinics, Retail Pharmacies and Others),Forecast Period (2023-2030).
The global insulin patch pump market is anticipated to grow at a CAGR of 9.8% during the forecast period. The growth of the market is attributed to factors such as the rising prevalence of diabetes, and increasing healthcare expenditure. According to the International Diabetes Federation, in 2021, 537 million adults (20-79 years) are living with diabetes - 1 in 10 around the globe. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. People million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes. Over 3 in 4 adults with diabetes live in low- and middle-income countries. Diabetes caused at least $966 billion dollars in health expenditure, a 316% increase over the last 15 years.
Moreover, the rising frequency of Food and Drug Administration (FDA) approvals and increasing awareness regarding advanced patch pumps are accelerating market growth. In May 2023, the US Food and Drug Administration cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for people six years of age and older with type 1 diabetes. These two devices, along with a compatible FDA-cleared integrated continuous glucose monitor (iCGM), developed a new system called the iLet Bionic Pancreas. This new automated insulin dosing (AID) system uses an algorithm to determine and command insulin delivery.
The global insulin patch pumps market is segmented based on the type, and distribution channel. Based on the type, the market is sub-segmented into disposable and reusable. Further, based on distribution channels, the market is sub-segmented into hospitals, private clinics, retail pharmacies, and others. Among the distribution channels, retail pharmacies is anticipated to grow over the forecast period owing to the assisting navigate symptoms, retail pharmacies handle a variety of prescriptions and give guidance to avoid side effects and drug interactions.
Among the types, disposable insulin patch pumps sub-segment is anticipated to hold a considerable share of the market, owing to the growing adoption of disposable insulin patch pumps to improve quality of life, reduce diabetes-related distress, increase patient satisfaction, and increasing environment concern. Thus, the market players are entering into partnerships and collaborations for catering to the growing demand across the globe. For instance, in May 2023, Medtronic plc, entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch® device, a tubeless, wearable and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor (CGM), is expected to expand the company's ability to address the needs of more individuals with diabetes, no matter where they are in their treatment journey or preference for how they want their insulin delivered.
The global insulin patch pumps market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the North America regional market is expected to grow considerably over the forecast period, rising adoption among type 1 diabetes patients, and increasing healthcare expenditure.
Among all regions, Asia Pacific is expected to grow at the fastest CAGR over the forecast period due to factors such as the rapidly growing diabetic population and increasing awareness regarding advanced diabetes management solutions in the region. According to the International Diabetes Federation, India, and China account for the largest number of diabetes patients in the world. Most of the countries in this region are developing countries and the increase in obesity cases and growing socio-economic changes have fueled the occurrence of type I and type II diabetes. In Southeast Asia, the number of adults with diabetes is predicted to rise to 152 million by 2045, an increase of 68%. In the Western Pacific, the number of adults with diabetes is predicted to rise to 260 million by 2045, an increase of 27%.
In addition, increasing product launches and technological advancements in the field of insulin patch pumps are expected to aid regional growth. In October 2023, Shanghai Yiyu Technology Co., Ltd. revealed the latest generation A8 ultra-thin insulin patch pump Nano pump globally. The A8 ultra-thin insulin patch pump is the world's smallest, lightest, and thinnest catheterless patch pump.
The major companies serving the global insulin patch pump market include: F. Hoffmann-La Roche Ltd, Medtronic plc., Terumo Corp., Tandem Diabetes Care Inc., Insulet Corp., SOOIL Developments Co., Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2023, Medtronic plc agreed to acquisition EOFlow Co., Ltd., a company based in South Korea that makes a tubeless, disposable insulin pump on a patch. The company made a public tender offer to acquire all EOFlow's outstanding public shares for W971 billion ($738 million).
GLOBAL INSULIN PATCH PUMPS BY OTHER DISTRIBUTION CHANNELS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)